Dr. Joe Lennerz, Chief Scientific Officer of BostonGene and a pathologist by training, joins Chadi to break down next-generation sequencing (NGS) in simple terms, discussing why some patients undergo NGS while others do not, along with its advantages and limitations. He also explores the impact of NGS on treatment pathways, the practicality of minimal residual disease (MRD) detection, liquid biopsy, and circulating tumor DNA (ctDNA), and whether immediate action should be taken after MRD detection. Additionally, Dr. Lennerz examines multi-cancer early detection technologies, who should be tested, and the future need for regulatory oversight in this rapidly advancing field.
Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/
Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA
